ESTA — Establishment Labs Holdings Inc. stock price, charts and financials

Latest market price

69.30

-0.26-0.37%

Overview Short InterestFilings

ESTAQT54Establishment Labs Holdings Inc.·NASDAQ

Overview Short InterestFilings

69.30-0.37%

Loading chart...

Signal & projected range

Analyst consensus risingHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

BFLY-1.00%$7.88 NVCR-0.18%$16.69 UFPT+0.46%$276.69 INSP+5.55%$76.78 AXGN-2.34%$44.23 ATEC-0.97%$10.18 NEOG+1.32%$13.00 TMDX-0.28%$86.42

Snapshot

Index	-	P/E	-	EPS (ttm)	-1.31	Insider Own	-	Shs Outstand	29.43M	Perf Week	-2.31%

Market Cap	2.04B	Forward P/E	-	EPS next Y	-0.02	Insider Trans	-2.11%	Shs Float	26.95M	Perf Month	-8.04%

Enterprise Value	2.23B	PEG	-	EPS next Q	-0.26	Inst Own	-	Short Float	16.31%	Perf Quarter	-18.29%

Income	-39.00M	P/S	8.26	EPS this Y	8.27%	Inst Trans	-	Short Ratio	7.27	Perf Half Y	5.75%

Sales	247.00M	P/B	92.71	EPS next Y	98.70%	ROA	-11.05%	Short Interest	4.40M	Perf YTD	-4.91%

Book/sh	0.75	P/C	28.73	EPS next 5Y	-	ROE	-203.88%	52W High	97.59 -28.99%	Perf Year	77.24%

Cash/sh	2.41	P/FCF	-	EPS past 3/5Y	-	ROIC	-5.35%	52W Low	37.37 85.44%	Perf 3Y	31.50%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	9.21% 19.94%	Gross Margin	70.49%	Volatility	3.03% 3.76%	Perf 5Y	-4.94%

Dividend TTM	-	EV/Sales	9.04	EPS Y/Y TTM	56.33%	Oper. Margin	-7.63%	ATR (14)	3.04	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	2.52	Sales Y/Y TTM	48.80%	Profit Margin	-15.82%	RSI (14)	36.80	Recom	2.07

Dividend Gr. 3/5Y	-	Current Ratio	3.84	EPS Q/Q	31.58%	SMA20	-3.60%	Beta	1.05	Target Price	102.00

Payout	0.00%	Debt/Eq	10.96	Sales Q/Q	33.33%	SMA50	-13.76%	Rel Volume	0.42	Prev Close	69.56

Employees	1,004	LT Debt/Eq	10.46	Earnings	Nov 04	SMA200	-5.72%	Avg Volume	554.79K	Price	69.30

IPO Date	Jul 19, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-15.78% 2.66%	Net Debt/EBITDA	-28.76	Volume	230,404	Change	-0.37%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-13-26	Upgrade	Citigroup	Neutral → Buy
Aug-06-26	Reiterated	Canaccord Genuity	Buy	$85 → $105
Aug-06-26	Reiterated	Needham	Buy	$84 → $95
Aug-06-26	Reiterated	BTIG	Buy	$86 → $103
Jul-15-26	Reiterated	Mizuho	Outperform	$70 → $105
Dec-31-25	Reiterated	BTIG	Buy	$81 → $86
Dec-17-25	Reiterated	Canaccord Genuity	Buy	$85
Dec-10-25	Reiterated	Needham	Buy	$70 → $84
Nov-14-25	Reiterated	BTIG	Buy	$70 → $81
Nov-06-25	Reiterated	Needham	Buy	$70

Latest News· Times ET

Sep-09-26

Sep-09-2601:36AM

Establishment Labs: Procedure Economics Strengthens The Bull Caseseekingalpha.com

Sep-05-26

Sep-05-2608:30AM

Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze.Yahoo

Sep-01-26

Sep-01-2608:00AM

A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capturegurufocus.com

Aug-28-26

Aug-28-2610:20AM

Baron Discovery Fund Q2 2026 Portfolio ActivitySeekingAlpha

Aug-26-26

Aug-26-2610:16PM

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives Average Rating of “Moderate Buy” from Brokeragesdefenseworld.net

Aug-23-26

Aug-23-2611:54PM

Deutsche Bank AG Buys New Holdings in Establishment Labs Holdings Inc. $ESTAdefenseworld.net

Aug-13-26

Aug-13-2610:39AM

Citigroup Upgrades Establishment Labs Hldgs to Buy, Maintains Price Target to $92Benzinga

Aug-07-26

Aug-07-2607:53AM

JP Morgan Maintains Overweight on Establishment Labs Hldgs, Raises Price Target to $95Benzinga

Aug-06-26

Aug-06-2602:24PM

Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcriptseekingalpha.com

09:05AM

Establishment Labs Q2 Earnings Call Highlightsmarketbeat.com

06:51AM

Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimateszacks.com

04:00AM

Establishment Labs® Reports Second Quarter 2026 Financial Resultsbusinesswire.com

Jul-31-26

Jul-31-2604:35AM

Jim Cramer: Bending Spoons Is A ‘Really Good’ Software Company, Recommends Buying This Industrial StockBenzinga

Jul-23-26

Jul-23-2604:00AM

Establishment Labs® to Announce Second Quarter 2026 Financial Results on August 6businesswire.com

Jul-20-26

Jul-20-2611:14PM

AlTi Global Inc. Makes New Investment in Establishment Labs Holdings Inc. $ESTAdefenseworld.net

Company

Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	247	211	166	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	73	65	57	—	—	—	—	—	—
Gross Profit	174	146	110	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	125	165	140	—	—	—	—	—	—
Research and Development	20	20	20	—	—	—	—	—	—
Other Operating Expense	47	0	0	—	—	—	—	—	—
Operating Income	-19	-39	-50	—	—	—	—	—	—
Interest Expense	27	25	21	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	0	6	-14	—	—	—	—	—	—
Net Income Before Taxes	-48	-58	-85	—	—	—	—	—	—
Income Taxes	-9	-7	0	—	—	—	—	—	—
Consolidated Net Income	-39	-51	-85	—	—	—	—	—	—
Net Income From Continuing Operations	-39	-51	-85	—	—	—	—	—	—
Net Income	-39	-51	-85	—	—	—	—	—	—
EPS (Recurring)	-1.31	-1.72	-3.00	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-1.31	-1.72	-3.00	—	—	—	—	—	—
EPS (Diluted)	-1.31	-1.72	-3.00	—	—	—	—	—	—
EBITDA	-6	-22	-56	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	8.42	10.36	7.77	—	—	—	—	—	—
Gross Margin	70.45	69.19	66.27	—	—	—	—	—	—
Operating Margin	-7.69	-18.48	-30.12	—	—	—	—	—	—
Net Margin	-15.79	-24.17	-51.20	—	—	—	—	—	—
Shares Outstanding	30	30	28	—	—	—	—	—	—
Market Capitalization	2,079	2,186	1,290	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JW Asset Management, LLC	other: See footnote 3	May 28 '26	Sale	72.89	65,100	4,745,139	2,890,582	May 28
JW Asset Management, LLC	other: See footnote 3	May 27 '26	Sale	72.50	113	8,193	2,955,682	May 28
JW Asset Management, LLC	other: See footnote 3	May 26 '26	Sale	74.39	25,320	1,883,555	2,955,795	May 28
JW Asset Management, LLC	10% Owner	May 21 '26	Sale	71.40	16,999	1,213,729	2,981,115	May 22
JW Asset Management, LLC	10% Owner	May 20 '26	Sale	70.56	3,580	252,605	2,998,114	May 22
Chacon Quiros Juan Jose	Director	May 06 '26	Sale	75.42	105,000	7,918,872	927,504	May 08
JW Asset Management, LLC	10% Owner	May 06 '26	Sale	75.63	60,000	4,537,500	3,001,694	May 08
Chacon Quiros Juan Jose	Director	May 04 '26	Sale	70.48	7,751	546,308	1,032,504	May 04
Chacon Quiros Juan Jose	Director	May 01 '26	Sale	70.78	67,249	4,759,569	1,040,255	May 04
Chacon Quiros Juan Jose	Director	Apr 27 '26	Sale	66.26	2,180	144,439	1,107,504	Apr 27
Chacon Quiros Juan Jose	Director	Apr 24 '26	Sale	65.78	30,178	1,984,969	1,109,684	Apr 27
Chacon Quiros Juan Jose	Director	Apr 23 '26	Sale	65.43	42,642	2,790,070	1,139,862	Apr 27
Chacon Quiros Juan Jose	Director	Apr 14 '26	Sale	65.23	37,500	2,446,050	1,182,504	Apr 16
SCHUTTER EDWARD J	Director	Apr 02 '26	Option Exercise	4.11	36,780	151,166	175,382	Apr 02
Chacon Quiros Juan Jose	Director	Mar 25 '26	Sale	60.08	3,575	214,768	1,220,004	Mar 27

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.